its b-catenin signalling pathway. Cell viability and apoptosis were examined in celecoxib-treated cells or after b-catenin knockdown in vitro. Analyses were performed to detect glycogen synthase kinase (GSK)-3b, phosphorylated GSK-3b, bcatenin, c-Myc and cyclin D1 proteins, and mRNA levels of b-catenin, c-Myc and CCND1 (encoding cyclin D1). b-Catenin was shown to be required for MG63 cell survival and celecoxib exerted an inhibitory effect on the viability of cultured MG-63 cells in a timeand dose-dependent manner. b-Catenin protein decreased in the cytosol and nucleus following celecoxib treatment (from 6 h after initiation of treatment onwards; lowest protein levels were reached at > 72 h). Significant reductions in b-catenin, c-Myc and CCND1 mRNA were observed. Celecoxib inhibited MG-63 cell viability, possibly by activating GSK-3b and inhibiting b-catenin-dependent gene transcription, suggesting a role for celecoxib in osteosarcoma treatment. KEY WORDS: b-CATENIN; GLYCOGEN SYNTHASE KINASE (GSK)-3b; CELECOXIB; MG-63 CELL LINE; OSTEOSARCOMA; RNA INTERFERENCE (RNAI) J-J Xia, L-B Pei, J-P Zhuang et al. Celecoxib targets b-catenin in osteosarcoma
Introduction
Osteosarcoma is the most common type of bone cancer: it accounts for 35% of primary bone malignancies and is ranked sixth among the leading cancers in children < 15 years of age. 1 Despite advancements in cancer therapy, the 5-year death rate for osteosarcoma patients remains at 40%. 2 The Wnt/β-catenin signalling pathway has been suggested to be a cyclo-oxygenase (COX)-2-independent target for nonsteroidal anti-inflammatory drugs (NSAIDs) in cancer cells. 3 -5 In normal cells, β-catenin is present on the cytoplasmic side of the cell membrane and functions to support cell-cell adhesion. In tumour cells, however, βcatenin may aberrantly accumulate in the cytosol and further translocate into the nucleus, where it acts as a coactivator for the transcription of a set of target genes including c-Myc, CCND1 (encoding cyclin D1), MMP7 (encoding matrix metalloproteinase 7) and NRCAM (encoding neuronal cell adhesion molecule). 6 -9 Although the development of anticancer β-catenin inhibitors is currently a primary
Materials and methods b-CATENIN KNOCKDOWN BY RNAI
Oligonucleotides with a random sequence (negative control small interfering RNA [siRNA] ) and a sequence complementary to β-catenin mRNA (β-catenin siRNA) were designed using BLOCK-iT™ RNAi (RNA interference) Designer (Invitrogen, Carlsbad, CA, USA) and synthesized for cloning into the RNAi vector pRNAi-hU6.2/lenti (Biomics, Nantong, Jiansu, China). Lentiviral particles were prepared by transfecting 293FT lentiviral packaging cells (ViraPower™ Lentiviral Expression System; Invitrogen) using Lipofectamine™ 2000 (Invitrogen); the concentration of RNAi vector pRNAi-hU6.2/lenti viral particles was about 1.7 × 10 7 viral particles/ml.
The human osteosarcoma cell line MG-63 was obtained from the Cell Resources Centre at the Shanghai Institutes for Biological Sciences (Chinese Academy of Sciences, Shanghai, China) and maintained in minimum essential medium (Gibco ® , Carlsbad, CA, USA) supplemented with 10% fetal calf serum at 37°C in a humidified incubator under 6.5% carbon dioxide. To infect MG-63 cells with lentiviral particles, exponentially growing cells were seeded into 10-cm culture plates at 30 -50% confluency. Lentiviral particles containing either the control siRNA or β-catenin siRNA were added at a multiplicity of infection of 50. At 6 h after infection, the medium was refreshed and the cells were incubated for a further 48 h before being plated for celecoxib treatment for 48 h, as described below. Untransfected and transfected cells at a density of 1 × 10 4 cells/100 µl were analysed by MTT (3-(4,5dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide) and apoptosis assays as described below.
MTT CELL VIABILITY ASSAY
The MG-63 cells were plated in 96-well plates at a density of 1 × 10 4 cells/100 µl. After 24 h incubation in serum-free medium, cells were treated with celecoxib (International Laboratories, Pleasantville, NY, USA) at concentrations of 0, 10, 50 and 100 µM for 24, 48 and 72 h. At 4 h before the end of each treatment, 10 µl of freshly prepared MTT (5 mg/ml) was added to each well and incubation was continued. At the end of the incubation period, the culture medium was removed and an equal volume of dimethyl sulphoxide was added to dissolve the MTT crystals. The optical density (OD) of each well was measured at a wavelength of 490 nm using a plate reader (Thermo Labsystems, Waltham, MA, USA). Percentage inhibition of cell viability was calculated as (1 -[OD treated /OD untreated ]) × 100. All experiments were repeated six times.
ANNEXIN V/PI APOPTOSIS ASSAY
The MG-63 cells at a density of 1 × 10 4 cells/100 µl were treated with 100 µM celecoxib for 0, 24, 48 and 72 h. At the end of each treatment period, approximately 1 × 10 5 cells were washed with 0.01 M phosphatebuffered saline (PBS), pH 7.3, then rinsed with 1 × binding buffer (300 mM NaCl, 50 mM Tris-HCl, 10 mM imidazole, pH 8.0), resuspended in 200 µl of 1 × binding buffer, and 5 µl of annexin V and 10 µl of propidium iodide (PI) were added. The cells were then incubated at room temperature for 15 min in the dark. To measure the proportion of apoptotic cells in each group, cells were then subjected to flow cytometry analysis using a J-J Xia, L-B Pei, J-P Zhuang et al.
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FACSCalibur™ flow cytometer (BD Biosciences, San Jose, CA, USA) and the data were analysed using ModFit LT™ software (Verity Software House, Topsham, ME, USA). All experiments were repeated six times.
WESTERN BLOT ANALYSIS
The MG-63 cells at a density of 1 × 10 4 cells/100 µl were treated with 100 µM celecoxib for 0, 6, 12, 24, 48 and 72 h. Antibodies against human β-catenin, glycogen synthase kinase-3β (GSK-3β), phospho-Ser 9 -GSK-3β, c-Myc and cyclin D1 proteins were purchased from Abcam (Cambridge, MA, USA). Isotype-matched horseradish peroxidase-conjugated secondary antibodies were purchased from Zhongshan Golden Bridge Biotechnology Co. Ltd (Beijing, China). Total protein was extracted in radioimmunoprecipitation assay lysis buffer. Nuclear proteins were extracted as described previously. 11 Equivalent amounts of total cell proteins were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis using a 12% gel and electrotransferred to nitrocellulose membranes. The membranes were blocked with BLOTTO (5% non-fat dry milk and 0.1% Tween 20 in 0.01 M PBS, pH 7.3) and incubated with the various primary antibodies, all at a dilution of 1:200, overnight at 4°C. After washing with 0.01 M PBS containing 0.1% Tween 20 (PBS-T), the membranes were incubated with appropriate horseradish peroxidase-conjugated secondary antibodies (1:2000 dilution) for 1 h at 20°C and then washed three times with PBS-T. The antibody-bound proteins were detected using a 3,3′-diaminobenzidine (DAB) detection kit (Zhongshan Golden Bridge Biotechnology Co. Ltd). Membranes were stripped and reprobed with antibodies to β-actin and histone H3 as internal protein loading controls for total cell lysates and nuclear protein fractions, respectively.
REAL-TIME QUANTITATIVE PCR
The MG-63 cells were harvested in TRIzol TM (Invitrogen, USA) to extract total RNA. An aliquot (2 µg) of each RNA sample was subjected to reverse transcriptionpolymerase chain reaction (RT-PCR) using SYBR ® PrimeScript ® RT-PCR kit II (Takara Biotechnology, Dalian, China) and the Mx3000P™ real-time PCR system (Stratagene, Foster City, CA, USA) according to the manufacturer's instruction. The primers used were synthesized by Jinsite Biotechnology (Nanjing, China) and had the following sequences:
The cycling programme involved preliminary denaturation at 95°C for 10 min, followed by 50 cycles of denaturation at 95°C for 15 s, annealing at 60°C for 35 s and elongation at 60°C for 30 s.
The relative mRNA levels of each target gene transcript were determined as the difference in the threshold cycle number (ΔC t ), using the threshold cycle number of the β-actin internal control as a reference. All experiments were repeated six times.
STATISTICAL ANALYSIS
Statistical analyses were carried out using the SPSS ® statistical package, version 11.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Data are presented as the mean ± SE. Statistical analysis was performed using oneway analysis of variance followed by Dunnett's t-test. A P-value < 0.05 was considered to be statistically significant. 
Results

CELECOXIB AND MG-63 CELL VIABILITY
Celecoxib exerted an inhibitory effect on MG-63 cell viability in a dose-and timedependent manner; compared with untreated cells, the cell viability was significantly reduced at all concentrations of celecoxib at 48 h and at 72 h (P < 0.05) but not at 24 h compared with baseline (0 µM celecoxib; Fig. 1 ). By 72 h, treatment with 100 µM celecoxib resulted in 68% inhibition of cell viability compared with baseline. This was due to a significant increase in the proportion of apoptotic cells (P < 0.01) from 24 h onwards following treatment with celecoxib ( Fig. 2 ).
b-CATENIN AND MG-63 CELL SURVIVAL
Significantly lower levels of β-catenin protein were observed in cells transfected with βcatenin siRNA compared with untransfected normal MG-63 cells or cells transfected with control siRNA (P < 0.01; Fig. 3A ); β-catenin was detected in both the cytoplasm and nucleus. In addition, β-catenin was required for MG-63 cell survival; inhibition of βcatenin using siRNA-β-catenin was associated with a significantly increased rate of apoptosis compared with normal control untransfected MG-63 cells or cells transfected with empty vector (P < 0.01; Fig. 3B ).
b-CATENIN DOWN-REGULATION AND SIGNALLING IN MG-63 CELLS
Treatment with 100 µM celecoxib resulted in significant down-regulation of β-catenin compared with baseline (0 h); levels of βcatenin protein and mRNA decreased significantly in a time-dependent manner from 6 h after celecoxib treatment (P < 0.05 or P < 0.01; Fig. 4A -4C ). The reduction in βcatenin protein levels occurred in both the cytoplasm and nucleus (Fig. 4A, 4B) .
Expression of the β-catenin target genes c-Myc and CCND1 was significantly reduced at both the mRNA and protein levels from 12 h (24 h for cyclin D1 protein) after treatment with 100 µM celecoxib (P < 0.05 Fig. 5A -5D ). Inhibition of βcatenin (6 h after treatment; Fig. 4 ) preceded inhibition of c-Myc and CCND1 gene expression, which occurred at 12 h after treatment ( Fig. 5 ), suggesting a cascade effect following celecoxib treatment 
GSK-3b ACTIVATION
After treatment with 100 µM celecoxib, the total GSK-3β protein level was unaffected ( Fig. 6A ) but the levels of phosphorylated GSK-3β were significantly reduced in response to treatment with celecoxib, in a time-dependent manner, from 6 h onwards (P < 0.05; Fig. 6B ). This indicates that celecoxib down-regulated β-catenin by activating GSK-3β.
Discussion
The present study on the in vitro effects of celecoxib, a COX-2 selective NSAID, on the human osteosarcoma cell line MG-63 revealed that treatment with celecoxib inhibited cell viability, probably due to the induction of apoptosis, and resulted in down-regulation of β-catenin at both the protein and mRNA levels. The reduction in βcatenin protein after celecoxib treatment was possibly caused by increased GSK-3β activation and a subsequent increase in βcatenin degradation. These experiments also confirmed that β-catenin was required for MG-63 cell survival and proliferation, and suggested a mechanistic link between COX-2 inhibition and β-catenin-dependent cell viability, indicating a potential application for celecoxib in β-catenin-targeted cancer therapies.
Lines of evidence show that β-catenin accumulation is common in human colon cancer and other tumours. 3 -5 Although the elevated β-catenin levels found in such tumours play important roles in tumour progression, the role of the β-catenin pathway in osteosarcoma has previously been unclear. Haydon et al. 12 showed that deregulation of βcatenin signalling commonly occurs in osteosarcoma and suggested that such signalling may represent an important mechanism in disease progression, although further examinations were not performed. In The present study also provided experimental evidence that celecoxib may be effective for treating osteosarcoma. Epidemiological and clinical studies suggest that COX-2 inhibitors may have anticancer effects. 13 -15 In particular, celecoxib has been shown to act as an inhibitor of proliferation in several tumour cell types. 16, 17 The antitumour effects of celecoxib depend on its COX-2-inhibiting potency, i.e. its regulation of the prostaglandin pathways. 18 COX-2independent mechanisms have been identified 19 and many cell signalling pathways are known to activate COX-2 expression, such as the phosphatidylinositol 3-kinase (PI3K)/Akt or Wnt/β-catenin pathways. 20 In particular, the Wnt/βcatenin pathway is a classical pathway that has been suggested to be a COX-2-independent target for NSAIDs in cancer cells. 21 Thus, we examined whether βcatenin was a necessary component for the growth and proliferation of MG-63 cells. Previous studies have established that high levels of β-catenin are correlated with tumourigenesis in several tumour types, suggesting that it could be a downstream target of COX-2 inhibitors. 22 -24 The present study also indicated that β-catenin is a likely downstream effector molecule following celecoxib treatment.
The Wnt proteins bind to cell surface receptors of the 'frizzled' family of G proteincoupled receptor proteins, causing receptors to activate 'dishevelled' family proteins, ultimately resulting in a change in the amount of β-catenin that reaches the nucleus. 25 In non-transformed cells, β-catenin becomes phosphorylated and associates with multiprotein complexes containing GSK-3β, protein phosphatase 2 (PP2A), axin and βtransducin repeat-containing protein (β-TrCP). 26 Phosphorylated β-catenin is then recognized by the ubiquitin ligase β-TrCP within these complexes and is destined for proteasomal degradation. 27, 28 On oncogenic transformation, GSK-3β is phosphorylated and, therefore, functionally inhibited leading to β-catenin accumulation and increased intranuclear levels of β-catenin. In the nucleus, β-catenin is associated with the High Mobility Group box of transcription factor LEF1/TCF family members to promote the transcription of downstream gene targets including COX-2, c-Myc and CCND1. 29, 30 The present study demonstrated that high levels of β-catenin were present in untreated MG-63 cells, and this protein was detected in both the cytoplasm and nucleus. These findings are consistent with previously published data, 4 and suggest that celecoxib down-regulates β-catenin in MG-63 cells at least, in part, by inhibiting β-catenin transcription. In human colon carcinoma cells, Maier et al. 3 found that the anticarcinogenic effects of celecoxib could be partly explained by β-catenin degradation in human colon carcinoma cells, and celecoxib may affect osteosarcoma cells in a similar manner.
The present study revealed that celecoxib exerted a time-and dose-dependent inhibitory effect on the viability of cultured MG-63 cells and caused them to undergo apoptosis. Western blot analysis confirmed that β-catenin was decreased in both the cytosol and the nucleus upon celecoxib treatment, as early as 6 h into treatment, with the lowest protein level reached after 72 h. Following the reduction in β-catenin protein levels, significant down-regulation of its downstream target genes, c-Myc and CCND1, was observed at both the mRNA and protein levels. This suggested that treatment with celecoxib activates a signalling cascade that leads to a decrease in β-catenin followed by increased apoptosis.
Interestingly, the present study demonstrated that the total GSK-3β protein level was unaffected, whereas there was a significant reduction in the levels of phosphorylated GSK-3β in response to treatment with celecoxib, which could potentially increase levels of the complexes of GSK-3β, PP2A, axin and β-TrCP. Finally, more β-catenin was degraded in response to treatment with celecoxib. Thus, in the present study, it is possible that celecoxib also down-regulated β-catenin by activating, i.e. dephosphorylating, GSK-3β. Dephosphorylation of GSK-3β leads to phosphorylation of β-catenin and subsequent degradation of phosphorylated β-catenin. 31, 32 The association between the dephosphorylation of GSK-3β and decreased β-catenin accumulation following celecoxib treatment that was observed in the present study suggests a potentially important oncogenic mechanism for tumour cells, including osteosarcoma cells. These data suggest a novel COX-2-independent molecular mechanism for the actions of celecoxib in MG-63 cells.
Although the causative relationship between GSK-3β and β-catenin in celecoxibinduced MG-63 cytotoxicity requires further evalunation, other work has revealed that celecoxib inhibits the proliferation of MG-63 cells via a PI3K/Akt-dependent pathway. 11 These observations are in line with the present study, since there is an interconnection between the PI3K/Akt and Wnt/β-catenin pathways. 33 It is important to note that, on phosphatase and tensin homologue inactivation and/or PI3K/Akt activation, GSK-3β in tumour cells is phosphorylated at serine-9 and becomes inactive. To this end, the present study indicates the need to investigate the possible dysregulation of other pathways involved in osteosarcoma development. Further studies
